Eli Lilly Stock Surges as Retatrutide Delivers 28% Weight Loss and Major Relief for Sleep Apnea & Knee Pain
Lilly stock jumps as new obesity drug helps people lose ~30% body weight and improve health, showing strong promise for future treatment.
/ 88 items
#NVO↓
Enobosarm Grabs Novo Nordisk’s Attention: Veru’s Big Obesity Breakthrough
Veru partnered with Novo Nordisk to test enobosarm + Wegovy for fat loss while keeping muscle; stock surged.
Hims & Hers Now Offers Affordable Generic Semaglutide in Canada
Hims & Hers offers cheaper generic semaglutide in Canada ($149/mo) with medical support for weight loss care.
Eli Lilly’s Retatrutide Delivers 28.3% Weight Loss in Phase 3 Trial, Analysts Stay Bullish
Eli Lilly’s retatrutide delivered 28.3% average weight loss at 80 weeks in Phase 3, with some patients reaching over 30% at 104 weeks. Analysts at Truist, Wolfe, and RBC stay bullish.
Novo Nordisk Raises Full-Year Guidance After Strong Wegovy Pill Launch
Novo Nordisk beat expectations as its new weight-loss pill sold fast, boosting sales, prescriptions, and improving its 2026 outlook.
Eli Lilly Dismisses Foundayo Liver Report as 'Statistical Background Noise' — RBC Maintains Outperform
Eli Lilly states that a post-launch report of hepatic failure for Foundayo (orforglipron) is not plausibly linked to the drug. RBC Capital describes it as “statistical background noise.”